A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-07 and is reviewed periodically as new material appears.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
In order to measure the time-dependent viscoelastic behavior of polymers dynamic mechanical analysis is often performed. Typically, in these measurements the one side of the hydrogel is subjected to a sinusoidal load in shear mode while the applied stress is measured with a stress transducer and the change in sample length is measured with a strain transducer. One notation used to model the sinusoidal response to the periodic stress or strain is:
== Effects == Baikiain is hypothesized to be the causative agent of illnesses resulting from consumption of food products containing tara flour. In several cases documented in 2022 people became ill after consuming meals containing tara flour with high concentrations of Baikian (3% dry weight). People experienced acute gastrointestinal and liver disease with clinical signs of hepatotoxicity. Baikiain was found not to harm mammalian or human cells in culture but did cause liver injury and depletion of glutathione in rodent models.
====== Cannabinoids ====== CBD is common in vape products. Conversion of CBD to THC can occur when CBD is heated to temperatures between 250 and 300 °C, potentially leading to its partial transformation into THC. CBD is one among the most suspected ingredients involved in VAPI. Synthetic cannabinoids are increasingly offered in e-cigarette form as "c-liquid".
Sources: en.wikipedia.org
==== Including Restore Britain prior to formation ==== In June 2025, former Reform MP Rupert Lowe launched a political organisation called "Restore Britain", advocating a harder line on immigration than Reform UK. Find Out Now were asked by the organisation to poll on a hypothetical new party led by Lowe. In February 2026, Lowe announced that Restore Britain would become a political party.
=== Euthanasia and assisted suicide === Pentobarbital can cause death when used in high doses. It is used for euthanasia for humans as well as animals. It is taken alone, or in combination with complementary agents such as phenytoin, in commercial animal euthanasia injectable solutions. As of 2021, the sodium salt of pentobarbital was considered the "drug of choice" for animal euthanasia in the United States and Canada.
The balance of threat theory is an offshoot of neorealism, coined in 1985 by Stephen M. Walt in an attempt to explain why balancing against rising hegemons has not always been consistent in history. In contrast to traditional balance of power theorists, Walt suggests that states balance against threats, rather than against power alone. The "balance-of-power theory is not wrong; it is merely incomplete. Power is one of the factors that affect the propensity to balance, although it is not the only one nor always the most important." The theory acknowledges that power is an extremely important factor in the level of threat posed by a state, but also includes geographic proximity, offensive capabilities, and perceived intentions. Balance of threat theory is an interesting adjunct to neorealism, because as a structural theory, neorealism only predicts that balances of power will form, not whether a particular state will balance or bandwagon (inter alia), or which state it might balance with. As Waltz put it: "balance of power theory is often criticized because it does not explain the particular policies of states. True, the theory does not tell us why state X made a certain move last Tuesday. To expect it to do so would be like expecting the theory of universal gravitation to explain the wayward pattern of a falling leaf.
Sources: en.wikipedia.org
Wool Bradford, Halifax and Huddersfield grew through the development of woollen mills. Leeds' traditional industry was the manufacturing of cloth while heavier engineering industries facilitated growth in South Leeds. The Heavy Woollen District covered towns such as Dewsbury, Batley, Morley, Ossett, Cleckheaton and Heckmondwike. The woollen and cloth industries declined throughout the twentieth century.
==== 1.G Viral fusion pores ==== 1.G.1 The Viral Pore-forming Membrane Fusion Protein-1 (VMFP1) Family 1.G.2 The Viral Pore-forming Membrane Fusion Protein-2 (VMFP2) Family 1.G.3 The Viral Pore-forming Membrane Fusion Protein-3 (VMFP3) Family 1.G.4 The Viral Pore-forming Membrane Fusion Protein-4 (VMFP4) Family 1.G.5 The Viral Pore-forming Membrane Fusion Protein-5 (VMFP5) Family 1.G.6 The Hepadnaviral S Fusion Protein (HBV-S Protein) Family 1.G.7 The Reovirus FAST Fusion Protein (R-FAST) Family 1.G.8 The Arenavirus Fusion Protein (AV-FP) Family 1.G.9 The Syncytin (Syncytin) Family 1.G.10 The Herpes Simplex Virus Membrane Fusion Complex (HSV-MFC) Family 1.G.11 Poxvirus Cell Entry Protein Complex (PEP-C) Family 1.G.12 The Avian Leukosis Virus gp95 Fusion Protein (ALV-gp95) Family 1.G.13 The Orthoreovirus Fusion-associated Small Transmembrane (FAST) Family 1.G.14 The Influenza Virus Hemagglutinin/Fusion Pore-forming Protein (Influenza-H/FPP) Family 1.G.15 The Autographa californica Nuclear Polyhedrosis Virus Major Envelope Glycoprotein GP64 (GP64) Family 1.G.16 The Human Immunodeficiency Virus Type 1 (HIV-1) Fusion Peptide (HIV-FP) Family 1.G.17 The Bovine Leukemia Virus Envelop Glycoprotein (BLV-Env) Family 1.G.18 The SARS-CoV Fusion Peptide in the Spike Glycoprotein Precursor (SARS-FP) Family 1.G.19 The Rotavirus Pore-forming Membrane Fusion Complex (Rotavirus MFC) Family 1.G.20 The Hantavirus Gc Envelope Fusion Glycoprotein (Gc-EFG) Family 1.G.21 The Epstein Barr Virus (Human Herpes Virus 4) Gp42 (Gp42) Family 1.G.22 The Cytomegalovirus (Human Herpesvirus 5) Glycoprotein gO (gO) Family
== Trial == Dias' trial started in November 2011. Alcina Dias identified him in court. On 3 October 2014, Dias, was sentenced to three years in jail for the kidnapping of Mendonça during the afternoon of his disappearance. On 18 March 2015, Dias was led to jail by his lawyer, after his arrest warrant had been issued. His sentence was reduced to two years for good behavior. On 29 March 2017, Dias was released.
== Endothelin == Agonists: Endothelin 1 Endothelin 2 Endothelin 3 IRL-1620 Sarafotoxin Antagonists: A-192621 Ambrisentan Aprocitentan Atrasentan Avosentan Bosentan BQ-123 BQ-788 Clazosentan Darusentan Edonentan Enrasentan Fandosentan Feloprentan Macitentan Nebentan Sitaxentan Sparsentan Tezosentan Zibotentan
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.